Company Performance Metrics
- Paul Y. Song: Chief Medical Advisor
André de Fusco: CEO and co-founder
Hawkeye has developed a new protease activity blood test for the early detection of lung cancer, when it is treatable. The Challenge: Early lung cancer is asymptomatic. By the time it is seen on chest scans it has been in the body for years and often spreads to other organs making it very difficult to stop. If detected early, lung cancer can be
treated with surgery or radiotherapy with a very high success rate. Today only 14% of lung cancers are caught early, and 84% of patients are late-detected after they experience symptoms and seek medical attention. Our Solution: Hawkeye’s LEAP (Lung Enzyme Activity Profile) diagnostic blood test quickly pre-screens the millions of people at risk for lung cancer to select the subset requiring full screening workups. This optimizes hospital resources, lowers healthcare costs, and reduces patient anxiety for greater peace of mind. LEAP can be repeated yearly as part of a regular health check-up. Our Technology: Hawkeye has developed a nanoscale protease biosensor to detect enzymatic misregulations in 18 biomarkers associated with lung cancer. When nanosensors built into the LEAP test come into contact with blood from a patient with lung cancer (any stage, any sub-type) they are detectable by Hawkeye’s machine-learning software algorithm. The LEAP workflow takes less than 2 hours and is compatible with standard molecular lab equipment.
